Combination of Ranibizumab and Targeted Laser Photocoagulation
Status:
Recruiting
Trial end date:
2024-07-30
Target enrollment:
Participant gender:
Summary
Intravitreal injections of Ranibizumab will be applied in all patients according to treatment
guidelines. The experimental group will receive additional targeted laser photocoagulation of
the peripheral areas of capillary non-perfusion (up to 4 laser treatments within 1st year of
the study). Based on the long-term observation after CoRaLa I study an importantly shorter
duration of treatment and a relevant reduction of the total number of re-injections in RL
patients is expected.